Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04174742 · ClinicalTrials.gov registry record

Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer

A clinical trial of Breast Cancer and Breast, sponsored by Wake Forest University Health Sciences.

Recruiting
Registry status
102
Enrollment target
2
Study locations

NCT04174742 is a study of Breast Cancer and Breast that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 102 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04174742, a study of Breast Cancer and Breast, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.

RECRUITING
Registry status
102 participants
Enrollment target
2
Study locations

Study Summary

The overall purpose of this study is to investigate whether younger subjects report pain with pegfilgrastim (or biosimilar substitution) more often and/or at higher levels (greater intensity) than older subjects.This study will be carried out throughout the course of your chemotherapy treatment, which will be prescribed by your study doctor. Participation in this study will not affect your cancer treatment.

Conditions Studied

Interventions

  • DRUG pegfilgrastim

Study Locations (2)

North Carolina

  • Levine Cancer Institute - Charlotte
  • Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2019-12-17
Est. Completion 2041-01

Sponsor

Wake Forest University Health Sciences

1,140 total trials

What the Registry Record Tells You About NCT04174742

The ClinicalTrials.gov registry entry for NCT04174742 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which pegfilgrastim is the first listed.

NCT04174742 reports 2 study locations spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT04174742 about?

NCT04174742 is a clinical study titled "Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer". The overall purpose of this study is to investigate whether younger subjects report pain with pegfilgrastim (or biosimilar substitution) more often and/or at higher levels (greater intensity) than older subjects.This study will be carried out throughout the course of your chemotherapy treatment, whi...

What is the current status of trial NCT04174742?

This trial is currently recruiting. The enrollment target is 102 participants. The study started on 2019-12-17. Estimated completion is 2041-01.

What conditions does trial NCT04174742 study?

This clinical trial studies the following conditions: Breast Cancer, Breast.

What interventions are being tested in trial NCT04174742?

The interventions under investigation include: pegfilgrastim (DRUG).

Who is sponsoring clinical trial NCT04174742?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04174742 being conducted?

This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.